Loading, Please Wait...
VANCOUVER, BC --(Marketwired - March 24, 2016) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC will be attending the 10th Annual International Partnering Conference, at BIO-Europe, Spring 2016, April 4-6, in Stockholm, Sweden. This is Europe's largest partnering conference within the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
As previously announced in January, APC has engaged Ella Korets-Smith, Principal at EKS Business Development, to lead the Company's business development effort. The Company is actively looking to partner its intellectual property, know-how and technologies for the development of superior protein therapeutics for cancer and other critical, unmet needs.
Since coming on board, Ms. Korets-Smith has represented APC at the Biotech Showcase and the Immunotherapy World 2016 Conferences. The description of the Company's portfolio of protein modification technologies and early stage targeted immunotherapeutics that was provided to conference attendees resulted in a full schedule of private face-to-face meetings. Further discussions have ensued post-conferences, followed by the signing of non-disclosure agreements that have allowed the Company to provide more detailed information regarding its technologies to satisfy the rapidly evolving interest in projects for which APC's labeling technologies can provide innovative solutions.
Allen Krantz, President and CEO, commented, "From its inception, APC has been engaged in protein modification, and more recently in applying such technologies to anticancer therapeutics. APC's recent attendance at top-level partnering conferences has highlighted the high demand for site-specific labeling technologies and has further reinforced the attractiveness and suitability of APC's platform to solve many problems in fast growing fields such as antibody therapeutics, building on the same technology that we have developed and continue to refine. Indeed, in this highly promising area of antibody therapeutics, which is estimated to reach sales of nearly $125 Billion USD by the year 2020, there are many parallels to APC's annexin-drug conjugate program, that our technologies are in a position to exploit. Building on the strong expressions of interest in APC technologies that are progressing in further discussions, the Company will be engaged with a full schedule of meetings at Bio-Europe."
Advanced Proteome Therapeutics Corporation (APC) is advancing a Site-Specific Protein Modification technology platform to enable the development of superior protein therapeutics. Using this technology, the Company has generated numerous and diverse modifications of Annexin V with superior binding and stability properties and are amenable to further labeling and conjugation for use in therapeutic applications. APC has preliminary data in pre-clinical animal models which show the potential of a number such entities, including APC 101, to act as an immunotherapeutic agent for cancer therapy. The company is also engaged in creating annexin-drug conjugates to rival antibody-drug conjugates and has prepared examples of such novel species.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
Alexander (Allen) Krantz
President and Chief Executive Officer
Tel: (617) 638-0340
Tel: (705) 888-2756